Selective GPR35 Antagonists - Probes 1 & 2
- PMID: 21433393
- Bookshelf ID: NBK50703
Selective GPR35 Antagonists - Probes 1 & 2
Excerpt
Although many known receptors that regulate addiction have been pharmacologically and biochemically well characterized, some orphan receptors with homology to known receptors of abuse (i.e. GPR35) remain uncharacterized. GPR35 is a G-protein coupled receptor, first identified in 1998 after a screen of a human genomic library. More recent RT-PCR studies have now confirmed the presence of GPR35 in dorsal root ganglion, the cerebellum and brain, as well as GPR35b, which was cloned from a human whole brain cDNA library. Thus, GPR35 regulation appears to have profound physiological and pathophysiological implications. In line with the specific aim of this project, the identified probes ML145 (CID-2286812) and ML144 (CID-1542103) represent selective antagonists for GPR35, but not for the related GPR55 orphan receptor, supporting the hypothesis that they do not produce non-specific interference with signaling directly at or downstream of the β-arrestin signaling pathway. These probes will serve as novel tools to delineate the biochemistry of GPR35 as potential therapeutics to selectively target pathways underlying pain and to enhance our understanding of the molecular basis of addiction.
Sections
Similar articles
-
Selective GPR35 Antagonists - Probe 3.2011 Mar 29 [updated 2011 Nov 21]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010–. 2011 Mar 29 [updated 2011 Nov 21]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010–. PMID: 22834041 Free Books & Documents. Review.
-
The therapeutic potential of orphan GPCRs, GPR35 and GPR55.Front Pharmacol. 2015 Apr 15;6:69. doi: 10.3389/fphar.2015.00069. eCollection 2015. Front Pharmacol. 2015. PMID: 25926795 Free PMC article. Review.
-
8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the orphan G protein-coupled receptor GPR35.J Med Chem. 2013 Jun 27;56(12):5182-97. doi: 10.1021/jm400587g. Epub 2013 Jun 17. J Med Chem. 2013. PMID: 23713606
-
GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors.Life Sci. 2013 Mar 19;92(8-9):453-7. doi: 10.1016/j.lfs.2012.06.039. Epub 2012 Jul 20. Life Sci. 2013. PMID: 22820167 Review.
-
From orphan to oncogene: The role of GPR35 in cancer and immune modulation.Cytokine Growth Factor Rev. 2024 Jun;77:56-66. doi: 10.1016/j.cytogfr.2024.03.004. Epub 2024 Mar 19. Cytokine Growth Factor Rev. 2024. PMID: 38514303 Free PMC article. Review.
References
-
- O’Dowd BF, Nguyen T, Marchese A, Cheng R, Lynch KR, Heng HH, Kolakowski LF, Jr, George SR. Discovery of three novel G-protein-coupled receptor genes. Genomics. 1998;47:310–3. - PubMed
-
- Guo J, Williams DJ, Puhl HL, 3rd, Ikeda SR. Inhibition of N-type calcium channels by activation of GPR35, an orphan receptor, heterologously expressed in rat sympathetic neurons. J Pharmacol Exp Ther. 2008;324:342–51. - PubMed
-
- Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, Riddick M, Dowell S, Staton PC, Green P, Shabon U, Bao W, Aiyar N, Yue TL, Brown AJ, Morrison AD, Douglas SA. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol. 2007;152:825–31. - PMC - PubMed
-
- Taniguchi Y, Tonai-Kachi H, Shinjo K. Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett. 2006;580:5003–8. - PubMed
Publication types
LinkOut - more resources
Full Text Sources